IFNG and acute lymphoblastic leukemia: However, in preclinical trials, the IL‐23 administration has showed direct anti‐tumour activity in several cancer types, including pediatric B‐ALL, exerting lower toxicity compared to IL‐12 treatment, possibly because of the lower induction of IFN‐γ.22